Assignee
CELLDEX THERAPEUTICS INC
US·23 granted patents·36 pending applications·64 citations·filing 2001–2024
Top patents by PatentIndex Score
59 records- 0195US10781267B2Methods of treating by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2018·Granted Sep 22, 2020·7 cites·22 claims
- 0294US10633444B2Agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2019·Granted Apr 28, 2020·12 cites·8 claims
- 0392US10184007B2Methods of treating a kit-associated cancer by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2017·Granted Jan 22, 2019·9 cites·20 claims
- 0490US11332537B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2021·Granted May 17, 2022·1 cites·26 claims
- 0590US10941201B2Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodiesCELLDEX THERAPEUTICS INC·Filed 2020·Granted Mar 9, 2021·2 cites·17 claims
- 0689US10793639B2Methods of treating by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2018·Granted Oct 6, 2020·3 cites·22 claims
- 0789US10189907B2Polynucleotides encoding anti-KIT antibodiesCELLDEX THERAPEUTICS INC·Filed 2016·Granted Jan 29, 2019·6 cites·34 claims
- 0887US2024150493A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0986US11891452B2Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·1 cites·20 claims
- 1086US10774146B2Treatment of eosinophil or mast cell related disordersCELLDEX THERAPEUTICS INC·Filed 2019·Granted Sep 15, 2020·2 cites·7 claims
- 1186US2025115663A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1285US11180566B2Antibodies that bind human CD27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2015·Granted Nov 23, 2021·4 cites·7 claims
- 1385US2024141063A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1485US2025346671A1Anti-pd-l1 antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1584US2024287180A1Treatment of eosinophil or mast cell related disordersCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1682US10865244B2Nucleic acids encoding agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2017·Granted Dec 15, 2020·1 cites·11 claims
- 1781US8362214B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)CELLDEX THERAPEUTICS INC·Filed 2009·Granted Jan 29, 2013·3 cites·11 claims
- 1881US7563876B2Human monoclonal antibodies to dendritic cellsCELLDEX THERAPEUTICS INC·Filed 2001·Granted Jul 21, 2009·11 cites·1 claims
- 1977US9649357B2Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)CELLDEX THERAPEUTICS INC·Filed 2016·Granted May 16, 2017·2 cites·8 claims
- 2076US2022324990A1Anti-cd27 and anti-pd-l1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2175US2025059291A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2273US11884699B2Anti-KIT antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·0 cites·20 claims
- 2372US11987626B2Treatment of eosinophil or mast cell related disordersCELLDEX THERAPEUTICS INC·Filed 2020·Granted May 21, 2024·0 cites·7 claims
- 2471US11459393B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·0 cites·7 claims
- 2571US2021147538A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2670US2022227877A1Antibodies that bind human cd27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2766US2014314780A1Compositions Using Antibodies Directed to GPNMB and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 2866US2011053863A1Methods of using flt3-ligand in the treatment of cancerCELLDEX THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 2966US2026055193A1Anti-kit antibody formulations and methodsCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3064US12297266B2Agonistic antibodies that bind human CD40 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2017·Granted May 13, 2025·0 cites·19 claims
- 3163US7316812B2Cells expressing anti-Fc receptor binding componentsCELLDEX THERAPEUTICS INC·Filed 2004·Granted Jan 8, 2008·0 cites·25 claims
- 3262US11884734B2Anti-MET antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·0 cites·16 claims
- 3361US2024409639A1Anti-ilt4 and anti-pd-1 bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3461US2018043014A1Compositions Using Antibodies Directed to GPNMB and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3560US9624300B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)CELLDEX THERAPEUTICS INC·Filed 2012·Granted Apr 18, 2017·0 cites·5 claims
- 3659US2024417459A1Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereofCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3759US2024117057A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3856US2024109961A1Treatment of chronic prurigoCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3955US2015044212A1Antibodies Directed to GPNMB and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4055US2022016168A1Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapyCELLDEX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4154US2018362443A1Uses of anti-her3 antibodies for treating cancerCELLDEX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4253US2019151351A1Regulators of anaplastic lymphoma kinase and uses thereofCELLDEX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4353US2016355593A1Antibody vaccine conjugates and uses thereforCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4451US2021077832A1Methods of treating cancer with dendritic cell mobilizing agentsCELLDEX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4550US2017218067A1Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4650US2016024192A1Molecular conjugates comprising human monoclonal antibodies to dendritic cellsCELLDEX THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4749US2015232948A1Method of Detecting and Treating Tuberous Sclerosis Complex Associated DisordersCELLDEX THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4848US2018057595A1Anti-MET Antibodies and Methods of Use ThereofCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4948US2018044429A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 5048US2022177593A1Anti-axl antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →